CRBP Stock Forecast & Price Target

Corbus Pharmaceuticals is supported by a pipeline that now shows clinical de-risking in both obesity and oncology, with CRB-913 posting 5.0% mean weight loss at 12 weeks at 60 mg and no serious treatment-related adverse events, while CRB-701 delivered a 42.9% confirmed ORR in OPSCC with a 5.6-month median PFS and 2.8% discontinuations. The CRB-913 data are especially important because they suggest peripheral CB1 inhibition can produce meaningful, dose-dependent weight loss without the historical psychiatric toxicity that limited earlier CB1 drugs, and the 240-patient CANYON-1 study keeps a September catalyst in view. Meanwhile, FDA clearance to begin the 250-patient TEMPO-1 registrational study in 2026, plus additional CRB-701 combination data expected in 1Q27, gives the company multiple near- and medium-term paths to value creation.

Corbus Pharmaceuticals is a clinical-stage company with no revenue in 2Q26 and a widening net loss of $35.0M versus $17.7M in 2Q25, underscoring persistent cash burn driven by rising R&D and operating costs. Its outlook is constrained by heavy dependence on unproven assets such as CRB-701 and CRB-913, where clinical failure, safety issues, or regulatory delays could prevent commercialization and undermine the thesis. Although $117.9M in cash, cash equivalents, and investments may fund operations into 2028, the need for additional equity financing, alongside strong competition from better-resourced peers, makes the risk-reward profile unattractive.